Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen
Oreshkova, N. ; Cornelissen, L.A.H.M. ; Haan, C.A.M. de; Moormann, R.J.M. ; Kortekaas, J.A. - \ 2014
Vaccine 32 (2014)41. - ISSN 0264-410X - p. 5323 - 5329.
rna recombination - rhesus macaques - in-vivo - protein - replication - epitope - nss
Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.
One health approach to Rift Valley fever vaccine development
Kortekaas, J.A. - \ 2014
Antiviral Research 106 (2014)24. - ISSN 0166-3542 - p. 24 - 32.
lethal virus challenge - saudi-arabia - immune-responses - rhesus macaques - mp-12 vaccine - south-africa - enzootic hepatitis - northeastern kenya - ifnar(-/-) mice - rvfv infection
Since its discovery in the 1930s, Rift Valley fever virus (RVFV) spread across the African continent and invaded the Arabian Peninsula and several islands off the coast of Southeast Africa. The virus causes recurrent outbreaks in these regions, and its continued spread is of global concern. Next-generation veterinary vaccines of improved efficacy and safety are being developed that can soon be used for the widespread vaccination of livestock. However, due to regulatory and economic challenges, vaccine manufacturers have been reluctant to develop a human vaccine. Recent innovations in veterinary vaccinology, animal models and licensing strategies can now be used to overcome these hurdles. This paper reviews the historical impact of RVFV on human health and proposes strategies to develop and license a next-generation vaccine for both animals and humans
Efficacy of three candidate Rift Valley fever vaccines in sheep
Kortekaas, J.A. ; Antonis, A.F.G. ; Kant-Eenbergen, H.C.M. ; Vloet, R.P.M. ; Vogel-Brink, A. ; Oreshkova, N.D. ; Boer, S.M. de; Bosch, B.J. ; Moormann, R.J.M. - \ 2012
Vaccine 30 (2012)23. - ISSN 0264-410X - p. 3423 - 3429.
north-american mosquitos - enzootic hepatitis - rhesus macaques - virus - disease - protein - transcription - protection - challenge - africa
Rift Valley fever virus (RVFV) is a mosquito-transmitted Bunyavirus that causes high morbidity and mortality among ruminants and humans. The virus is endemic to the African continent and the Arabian Peninsula and continues to spread into new areas. The explosive nature of RVF outbreaks requires that vaccines provide swift protection after a single vaccination. We recently developed several candidate vaccines and here report their efficacy in lambs within three weeks after a single vaccination. The first vaccine comprises the purified ectodomain of the Gn structural glycoprotein formulated in a water-in-oil adjuvant. The second vaccine is based on a Newcastle disease virus-based vector that produces both RVFV structural glycoproteins Gn and Gc. The third vaccine comprises a recently developed nonspreading RVFV. The latter two vaccines were administered without adjuvant. The inactivated whole virus-based vaccine produced by Onderstepoort Biological Products was used as a positive control. Five out of six mock-vaccinated lambs developed high viremia and fever and one lamb succumbed to the challenge infection. A single vaccination with each vaccine resulted in a neutralizing antibody response within three weeks after vaccination and protected lambs from viremia, pyrexia and mortality.
Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA
Huisman, W. ; Schrauwen, E.J.A. ; Tijhaar, E. ; Süzer, Y. ; Pas, S.D. ; Amerongen, G. van; Sutter, G. ; Rimmelzwaan, G.F. ; Osterhaus, A.D.M.E. - \ 2008
Veterinary Immunology and Immunopathology 126 (2008)3-4. - ISSN 0165-2427 - p. 332 - 338.
cytotoxic t-lymphocytes - semliki-forest-virus - envelope glycoprotein - protective immunity - subunit vaccines - rhesus macaques - 89.6p challenge - animal-model - tat protein - replication
In recent years it has become clear that cell-mediated immunity is playing a role in the control of lentivirus infections. In particular, cytotoxic T lymphocyte responses have been associated with improved outcome of infection, especially those directed against the regulatory proteins like Rev and Tat, which are expressed early after infection. Therefore, there is considerable interest in lentiviral vaccine candidates that can induce these types of immune responses. In the present study, we describe the construction and characterisation of expression vectors based on recombinant Semliki Forest virus system and modified vaccinia virus Ankara for the expression of feline immunodeficiency virus (FIV) accessory proteins Rev and OrfA. These recombinant viral vectors were used to immunize cats using a prime-boost regimen and the protective efficacy of this vaccination strategy was assessed after challenge infection of immunized cats with FIV.